Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Gathering Around Cancer 2020 | Osimertinib for EGFR-mutant lung cancer

Jarushka Naidoo, MBBCh, Beaumont Hospital, Dublin, Ireland, outlines the approval and reimbursement of osimertinib in patients with EGFR mutant non-small cell lung cancer, based on the results of the FLAURA study. (NCT02296125). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology)